Navigation Links
Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology Patented in U.S. and Mexico
Date:6/24/2009

FORT LAUDERDALE, Fla., June 24 /PRNewswire/ -- Argentech, Inc. (www.argentechinc.com) today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. and, recently, in Mexico as well. It also has patent protection overseas. (See www.silver100.com/patents.)

Recently, there has been a surge in the number of industrial and medically related products utilizing ionic silver, owing to its broad-spectrum antibacterial and antiviral qualities. University studies and regulatory approvals further attest to the antimicrobial powers of ionic silver, which is harmless to humans with normal use.

The mechanism of action by which ionic silver kills germs gives it this remarkable combination of characteristics. However, it's extremely unstable and requires a delivery mechanism to function.

The result of more than a million dollars in development, Opti-Silver was designed explicitly to optimize the delivery of silver ions in the human body.

"The Opti-Silver complex represents a quantum leap in utilizing ionic silver for internal human use," said Roger Leblanc, Ph.D., former director of the Departments of Chemistry and Advanced Microscopy at the University of Miami. "Nothing else even comes close to the efficiency of its unique delivery mechanism."

Donald Baird, Ph.D., former director of the Department of Chemistry at Florida Atlantic University, has called Opti-Silver "ingenious" and "unprecedented." (See www.silver100.com/reports.)

In November of 2007, the maker of a certain surface disinfectant was granted EPA approval to claim that its ionic silver product kills strains of SARS, Bird Flu, MRSA, influenza, and a range of other pathogens. Drs. Leblanc and Baird have written pointed reports stating that that surface disinfectant would be all but useless for internal human use, citing its lack of an appropriate delivery mechanism for the challenging electro-chemical environment of the human body.

"To a chemist," Dr. Baird stated, "Opti-Silver represents a brilliant chemical formulation that results in a far more efficient delivery mechanism for releasing silver ions in the body than has ever existed before."

"We have the technology and patents to support a business model that enables us to perform serious humanitarian work, by growing our business," said Jay Newman, CEO of Argentech. "And we have a game plan in place to roll this out to the public on a massive scale in a remarkably short time," he said.

A study has been designed, to be conducted at the world's largest clinical research center for pediatric drugs, which Argentech believes will prove the ability of ionic silver to prevent the vast majority of upper respiratory infections, including those that are viral in nature. Fighting viral infection is an area where solutions are still lacking and vitally needed.

"To fund the study, we're relying on wealthy individuals who really want to make a difference in human health on a worldwide scale," Newman said.

"It's not that we mind sharing stock with investors," he added. "We find that philanthropists tend to resonate far better with us, because they share the humanitarian priority behind our mission. It's not just about the numbers for us. It's both. We have to be successful to get this vital product to the people."

Charitable contributions can be made into a 501(C)(3) called the Foundation for Health Research, which will fund the study.

Meet Newman and hear the story at www.argentechinc.com/video1.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Argentech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. UCLA study identifies designer estrogen as potential MS drug
3. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
4. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
5. Potential new approach to treat cognitive impairments in schizophrenia
6. Nosespray vaccine using aloe vera has exciting potential, researcher says
7. Network approach identifies potential breast cancer susceptibility gene
8. Liver fibrosis will be treated by a potential target
9. Researchers study potential health benefits of natural chemicals in muscadine grape seeds
10. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
11. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & ... years in business this year, and they’re marking the milestone by undertaking a ... their patients. , It stands to reason that, given the central importance ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... has received a three-year grant totaling $975,000, renewing its funding from the Health ... Human Services. , This funding marks, the fourth time the HRSA administration has ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards ... after every reprocessing cycle, both between patient procedures and before storage, is a ... is as important to the prevention of disease transmission and nosocomial infection as ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled ... list for the fourth consecutive year. With 197% revenue growth over the ... the nation’s fastest growing companies. , Previous honors include ranking 86th on ...
(Date:8/16/2017)... TX (PRWEB) , ... August 16, 2017 , ... ... the United States, named Dr. Douglas J. Harrison, as the new Medical Director of ... be the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
Breaking Medicine Technology: